These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10977461)

  • 1. Critical overview of antihypertensive therapies: what is preventing us from getting there? Based on a presentation by Mark A. Munger, PharmD.
    Am J Manag Care; 2000 Mar; 6(4 Suppl):S211-21. PubMed ID: 10977461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future of antihypertensive treatment.
    Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients.
    Mazzaglia G; Ambrosioni E; Alacqua M; Filippi A; Sessa E; Immordino V; Borghi C; Brignoli O; Caputi AP; Cricelli C; Mantovani LG
    Circulation; 2009 Oct; 120(16):1598-605. PubMed ID: 19805653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004.
    Wong ND; Lopez VA; L'Italien G; Chen R; Kline SE; Franklin SS
    Arch Intern Med; 2007 Dec; 167(22):2431-6. PubMed ID: 18071164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hypertension in chronic kidney disease.
    Toto RD
    Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of risk.
    Hemmelgarn BR; Zarnke KB; Campbell NR; Feldman RD; McKay DW; McAlister FA; Khan N; Schiffrin EL; Myers MG; Bolli P; Honos G; Lebel M; Levine M; Padwal R;
    Can J Cardiol; 2004 Jan; 20(1):31-40. PubMed ID: 14968141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The problem of uncontrolled hypertension.
    Lindholm LH
    J Hum Hypertens; 2002 Aug; 16 Suppl 3():S3-8. PubMed ID: 12140722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stroke and coronary heart disease in treated hypertension -- a prospective cohort study over three decades.
    Almgren T; Persson B; Wilhelmsen L; Rosengren A; Andersson OK
    J Intern Med; 2005 Jun; 257(6):496-502. PubMed ID: 15910553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence with treatment in newly treated middle-aged patients with essential hypertension.
    Perreault S; Lamarre D; Blais L; Dragomir A; Berbiche D; Lalonde L; Laurier C; St-Maurice F; Collin J
    Ann Pharmacother; 2005 Sep; 39(9):1401-8. PubMed ID: 16076920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk stratification for the prevention of cardiovascular complications of hypertension.
    Girerd X; Giral P
    Curr Med Res Opin; 2004 Jul; 20(7):1137-42. PubMed ID: 15265258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens.
    Frishman WH
    Cardiol Rev; 2007; 15(5):257-63. PubMed ID: 17700384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cardiovascular risk in hemodialysis in Spain: prevalence, management and target results (MAR study)].
    Portolés J; López-Gómez JM; Aljama P
    Nefrologia; 2005; 25(3):297-306. PubMed ID: 16053011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertension and coronary heart disease risk factor management.
    Houston MC
    Aust Fam Physician; 1994 Feb; 23(2):243-5, 248-51. PubMed ID: 8161313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy.
    Burnier M
    Am J Hypertens; 2006 Nov; 19(11):1190-6. PubMed ID: 17070434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choice of antihypertensive drug in the diabetic patient.
    Ong HT; Cheah JS
    MedGenMed; 2005 May; 7(2):74. PubMed ID: 16369452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.